List of Excipients in Branded Drug DACOGEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Otsuka America Pharmaceutical Inc	DACOGEN	decitabine	59148-046	MONOBASIC POTASSIUM PHOSPHATE
Otsuka America Pharmaceutical Inc	DACOGEN	decitabine	59148-046	SODIUM HYDROXIDE

Dacogen Excipient Strategy and Commercial Opportunities for Decitabine

Last updated: September 24, 2026

Dacogen is an intravenous decitabine product supplied as a 50 mg lyophilized vial. Its U.S. formulation uses decitabine and monobasic potassium phosphate, with sterile water for reconstitution and further dilution before infusion.[1] The core drug patent position is mature, and the strongest commercial opportunities are therefore in formulation performance, hospital-use efficiency, supply reliability, ready-to-use presentation, and differentiated delivery rather than in exclusivity for decitabine itself.

The most attractive excipient opportunities are:

1. Improving reconstitution and solution stability.
2. Reducing preparation time and hazardous-drug handling.
3. Developing ready-to-administer or concentrated presentations.
4. Designing compatible containers, elastomers, and infusion systems.
5. Supporting oral or modified-release decitabine products that compete with or complement intravenous Dacogen.
6. Protecting manufacturing processes, lyophilization cycles, and stability profiles.

What is Dacogen and which excipients does the approved product contain?

Dacogen is the U.S. brand for decitabine for injection, a hypomethylating agent used to treat myelodysplastic syndromes. The approved regimen is generally 20 mg/m² by intravenous infusion over one hour, administered daily for five consecutive days in a treatment cycle.[1]

Dacogen formulation profile

Attribute	Dacogen specification
Active ingredient	Decitabine
Dosage form	Lyophilized powder for injection
Strength	50 mg per vial
Primary excipient	Monobasic potassium phosphate
Reconstitution	10 mL sterile water for injection
Reconstituted concentration	Approximately 5 mg/mL
Administration	Further dilution and intravenous infusion
Storage and handling	Controlled post-reconstitution handling and limited stability
Therapeutic area	Myelodysplastic syndromes and related hematologic malignancies

The product’s excipient system is intentionally limited. Monobasic potassium phosphate provides buffering capacity during reconstitution and storage. The formulation does not depend on a complex surfactant, preservative, or organic cosolvent system.

This simplicity creates both a barrier and an opportunity. A generic manufacturer can reproduce the core formulation with relatively few ingredients. A differentiated product must therefore demonstrate a meaningful pharmaceutical or commercial advantage, such as improved stability, shorter preparation time, lower particulate risk, reduced overfill, or better compatibility with infusion materials.

What formulation challenges define the Dacogen excipient strategy?

Decitabine is chemically unstable in aqueous solution, particularly under conditions that promote hydrolysis. The product is supplied as a freeze-dried powder to improve shelf life before use. Once reconstituted, the solution requires controlled handling and limited in-use storage.[1]

Key technical challenges

The main formulation challenges are:

• Maintaining decitabine potency during reconstitution and infusion.
• Controlling pH without accelerating degradation.
• Achieving rapid and complete cake dissolution.
• Avoiding precipitation or visible and subvisible particles.
• Preserving compatibility with bags, tubing, filters, and vial components.
• Supporting pharmacy workflow for repeated daily dosing.
• Controlling oxygen, moisture, and temperature exposure during manufacture and storage.

The excipient system must balance chemical stability against manufacturability. A stronger buffer is not automatically better. Excessive ionic strength, unsuitable pH, or elevated moisture can reduce stability or impair cake structure.

Excipient screening priorities

A development program would typically prioritize:

Formulation variable	Commercial relevance
Phosphate concentration	Controls pH and can affect stability and cake quality
pH range	Influences decitabine degradation and reconstitution performance
Bulking agent	Improves cake structure and handling
Cryoprotectant or lyoprotectant	Protects the active during freezing and drying
Surfactant	May reduce interfacial stress but can create compatibility and regulatory issues
Residual moisture	Directly affects solid-state stability
Oxygen exposure	May contribute to degradation and impurity formation
Container closure	Affects moisture ingress, adsorption, and extractables
Reconstitution volume	Determines preparation time and dosing flexibility

Any new excipient would need a clear role. For a mature injectable product, adding ingredients without a measurable benefit could increase regulatory burden and reduce commercial attractiveness.

What formulation patents could protect a Dacogen follow-on product?

The most defensible patent opportunities are likely to involve a defined composition combined with a measurable technical result. Broad claims covering decitabine plus a conventional buffer would face validity and obviousness risk because the marketed product already establishes a simple buffered lyophilized formulation.

Potential patentable claim areas

1. Stabilized lyophilized compositions

A patent could claim a narrowly defined range of:

• Decitabine concentration.
• Phosphate concentration.
• pH before and after reconstitution.
• Residual moisture.
• Cake density or porosity.
• Reconstitution time.
• Specified degradation-product limits.

The strongest claims would connect the composition to improved potency retention or longer in-use stability.

2. Ready-to-use or extended-stability solutions

A liquid decitabine formulation could have commercial value if it remains within specification long enough to support centralized pharmacy preparation, batch compounding, or off-site dispensing.

The challenge is that the liquid must preserve decitabine through manufacture, shipping, storage, dilution, and infusion. Stabilization strategies could involve pH control, oxygen management, low-temperature storage, specialized containers, or combinations of excipients.

3. Infusion-compatible compositions

Claims could cover decitabine formulations that maintain stability after dilution into specified infusion fluids or after contact with defined tubing and bag materials.

This area is commercially relevant because oncology pharmacies use standardized preparation systems. A formulation that reduces adsorption, precipitation, or filter blockage could support adoption even without a new active ingredient.

4. Container-closure systems

A product may obtain protection through a combination of formulation and packaging, including:

• Low-moisture elastomeric stoppers.
• Reduced-oxygen headspace.
• High-barrier vials.
• Specialized reconstitution devices.
• Closed-system transfer components.
• Pre-filled diluent and drug chambers.

These claims can be harder to design around than an excipient-only claim if the package delivers a measurable stability or safety advantage.

5. Lyophilization processes

Process claims may address:

• Freezing temperature and annealing.
• Primary and secondary drying conditions.
• Chamber pressure.
• Residual moisture targets.
• Reconstitution performance.
• Impurity control.

Process patents are most valuable when the final product has a distinctive analytical fingerprint or when the process materially improves yield and batch consistency.

What is the Orange Book status of Dacogen?

Dacogen’s principal U.S. exclusivity is mature. The product was approved by the FDA in May 2006, and its orphan-drug exclusivity period expired after seven years.[1,2]

U.S. exclusivity timeline

Milestone	Date or status
FDA approval of Dacogen	May 2006
Orphan-drug exclusivity	Expired in 2013
Core decitabine composition protection	Mature and expired
Current commercial status	Generic injectable competition
Orange Book strategy	Limited value from legacy product claims
Primary competitive barrier	Manufacturing, quality, supply, and clinical adoption

The FDA Orange Book is the controlling source for current listed patents and regulatory exclusivity. Legacy Dacogen protection does not create a durable barrier comparable with a recently launched specialty injectable.[2]

No material commercial strategy should rely on blocking generic entry through old decitabine composition claims. The practical IP focus should be on new formulations, presentation, manufacturing, and delivery systems.

When does Dacogen lose exclusivity and what does generic entry look like?

Dacogen lost meaningful market exclusivity years ago. Generic manufacturers can seek approval through an abbreviated new drug application if they demonstrate pharmaceutical equivalence, bioequivalence or applicable in vitro equivalence, and compliance with manufacturing requirements.[3]

Generic launch scenarios

Scenario	Likely market effect
Multiple suppliers with standard lyophilized vials	Price pressure and formulary substitution
Two or three reliable suppliers	Moderate price erosion with continued supply differentiation
Single-source disruption	Temporary pricing power for available suppliers
Ready-to-use entrant	Potential premium despite generic competition
Improved-stability entrant	Premium in high-throughput oncology centers
Oral decitabine product expansion	Structural pressure on IV volume

Generic decitabine injection is relatively accessible compared with complex biologics. The product does not require a biosimilar pathway. Its main technical barriers are sterile manufacturing, lyophilization capacity, impurity control, and supply reliability.

Which companies are challenging Dacogen?

The competitive field consists primarily of generic injectable manufacturers and specialty oncology suppliers rather than biosimilar developers. Public FDA approval records and commercial wholesaler listings should be used to identify the current approved suppliers because ownership, labeler status, and distribution arrangements change over time.[2,4]

The relevant competitive comparison is not only the number of ANDA holders. Hospital buyers also evaluate:

• Back-order history.
• Vial fill accuracy.
• Batch release consistency.
• Reconstitution time.
• Stability after preparation.
• Contracting terms.
• Availability of pharmacy-support materials.
• Ability to maintain supply during oncology-drug shortages.

How does Dacogen compare with oral decitabine and cedazuridine?

Inqovi, a fixed-dose oral combination of decitabine and cedazuridine, was approved by the FDA in 2020 for certain adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.[5]

Cedazuridine inhibits cytidine deaminase, increasing oral decitabine exposure. This changes the competitive equation for Dacogen because the product competes on administration route, site-of-care economics, and patient convenience rather than only on price.

Factor	Dacogen	Oral decitabine/cedazuridine
Route	Intravenous	Oral
Preparation	Pharmacy reconstitution and infusion	Tablet dispensing
Main excipient opportunity	Lyophilization, infusion compatibility, ready-to-use format	Tablet disintegration, stability, absorption, dose uniformity
Site of care	Infusion center or hospital	Outpatient or home administration
Manufacturing complexity	Sterile injectable and lyophilized product	Solid oral combination product
Competitive risk	Generic injectable erosion	Oral substitution and branded combination competition
IP profile	Mature decitabine product estate	Combination and oral-delivery protection

Oral decitabine products also create opportunities for excipient suppliers and formulation developers. Relevant technologies include moisture-protective coatings, modified-release systems, taste masking, tablet compression aids, and excipients that preserve dose uniformity at low drug loading.

What commercial opportunities exist for Dacogen excipients?

Ready-to-administer presentations

A ready-to-use or near-ready-to-use product could reduce pharmacy labor and preparation errors. The commercial value is greatest if the formulation provides:

• Extended refrigerated stability.
• Reduced manipulation.
• Compatibility with standard infusion bags.
• Reduced time from prescription to administration.
• Lower risk of incomplete reconstitution.
• Consistent dose recovery from the vial.

The product would likely compete on total cost of care rather than acquisition price alone.

Excipient and packaging supply

Suppliers can pursue recurring revenue through qualified sources of:

• Pharmaceutical-grade monobasic potassium phosphate.
• Lyophilization bulking agents.
• Low-peroxide surfactants, if required.
• Low-moisture stoppers.
• High-barrier glass or polymer containers.
• Single-use transfer devices.
• Compatible infusion bags and tubing.

For a mature generic, dual sourcing and supply continuity may be more valuable than a marginal ingredient-cost reduction.

Contract development and manufacturing

A CDMO with sterile lyophilization capacity can offer:

• Formulation screening.
• Cycle development.
• Analytical method development.
• Extractables and leachables studies.
• Container-closure integrity testing.
• Stability programs.
• Commercial-scale fill-finish.

The strongest commercial position comes from combining excipient expertise with validated sterile manufacturing. Ingredient supply alone is easier to replace.

Hospital pharmacy optimization

A differentiated decitabine product could target high-volume oncology centers with:

• Pharmacy batching.
• Automated compounding compatibility.
• Longer beyond-use periods supported by stability data.
• Closed-system transfer compatibility.
• Reduced vial waste.
• Standardized dose preparation.

A 50 mg vial can create dose-rounding and residual-volume issues because patient doses are calculated by body surface area. A formulation or packaging configuration that improves dose recovery or supports smaller dose increments could reduce waste.

What regulatory issues apply to a new Dacogen formulation?

A new injectable decitabine formulation would generally require an abbreviated pathway only if it meets applicable sameness and equivalence requirements. A meaningful formulation change may instead require a suitability petition, an ANDA with formulation differences, or a full 505(b)(2) application, depending on the product’s differences and regulatory justification.[3,6]

Key regulatory workstreams include:

• Demonstrating pharmaceutical equivalence.
• Characterizing degradation products.
• Establishing sterility and container-closure integrity.
• Validating reconstitution and dilution instructions.
• Assessing infusion-system compatibility.
• Conducting particulate and visible-inspection testing.
• Establishing in-use stability.
• Supporting any new excipient with FDA-acceptable safety information.
• Demonstrating dose recovery and uniformity.

A novel excipient or unusual concentration would increase regulatory complexity. A reformulator should first exploit established parenteral excipients and build differentiation through defined ratios, process controls, packaging, and stability data.

How strong is the Dacogen patent estate?

The legacy estate is weak as a barrier to standard generic injection. Decitabine is an established small molecule, Dacogen has been marketed since 2006, and orphan exclusivity has expired.[1,2]

Relative strength by protection type

Protection category	Relative strength	Commercial assessment
Decitabine composition	Low	Mature technology and generic availability
Basic phosphate-buffered formulation	Low	Likely vulnerable to design-around and prior art
Defined lyophilized composition	Moderate	Stronger if tied to stability or reconstitution results
Ready-to-use liquid formulation	Moderate to high	Depends on demonstrated stability and claim breadth
Container-closure system	Moderate	Useful when integrated with performance data
Lyophilization process	Moderate	Can protect manufacturing know-how and consistency
Oral decitabine combination	Higher	Separate product and combination-IP considerations
Hospital workflow and supply reliability	Non-patent moat	Can support commercial differentiation

Trade-secret protection is important for cycle parameters, impurity-control methods, filling conditions, and scale-up knowledge. These assets may remain valuable even where patent claims are narrow.

What patent litigation and settlement risks affect Dacogen?

Dacogen is unlikely to generate the level of Paragraph IV litigation associated with a recently launched blockbuster because its core exclusivity has expired and generic entry is established. Litigation risk is more likely to arise from:

• A newly patented ready-to-use formulation.
• A stabilized liquid or concentrated presentation.
• A proprietary container-closure system.
• A combination product involving oral decitabine.
• Manufacturing-process patents with commercial relevance.

Settlement agreements could involve launch dates, licenses, authorized-generic arrangements, or restrictions tied to formulation patents. Any agreement should be reviewed for antitrust risk, product-supply obligations, and its treatment of later-developed formulations.

Key Takeaways

• Dacogen is a mature intravenous decitabine product with limited legacy exclusivity value.
• The approved product uses a simple excipient system centered on monobasic potassium phosphate and lyophilized presentation.
• The strongest formulation opportunity is improved aqueous stability, reconstitution, dilution compatibility, or pharmacy workflow.
• A basic buffer substitution is unlikely to create durable differentiation without supporting performance data.
• Ready-to-administer and extended-stability products could command commercial value despite generic competition.
• Packaging, transfer systems, and lyophilization processes may provide stronger protection than broad excipient claims.
• Oral decitabine/cedazuridine creates a route-of-administration threat and a separate solid-dose excipient opportunity.
• Generic success depends on sterile manufacturing, supply continuity, quality performance, and contracting.
• No biosimilar pathway applies to Dacogen because decitabine is a small-molecule drug.
• The commercial moat is more likely to come from formulation execution and hospital economics than from the expired core compound estate.

FAQs

Can monobasic potassium phosphate alone support a new Dacogen patent?

Usually not. A patent position would be stronger if it claimed a defined concentration and pH range tied to improved decitabine stability, reconstitution, impurity control, or in-use performance.

Is a ready-to-use decitabine injection commercially attractive?

Yes, if it materially extends stability, reduces pharmacy preparation, limits hazardous handling, and maintains compatibility with standard infusion systems. The product would compete on workflow and total treatment cost rather than only vial price.

Does Dacogen have biosimilar competition?

No. Dacogen contains the small-molecule drug decitabine. Follow-on products use generic-drug pathways rather than the biosimilar framework.

Which excipient technologies are most relevant to oral decitabine?

Moisture protection, tablet robustness, dose uniformity, disintegration control, and excipient systems that support consistent exposure with cedazuridine are the main areas of interest.

What is the largest non-patent barrier to launching generic decitabine injection?

Reliable sterile lyophilization and supply continuity. Oncology providers may favor a supplier with consistent availability, low defect rates, and predictable preparation performance even when several products have equivalent FDA approvals.

References

1. U.S. Food and Drug Administration. (2023). Dacogen (decitabine) for injection: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. [Orange Book].
3. U.S. Food and Drug Administration. (2017). ANDA submissions: Content and format of an ANDA.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
5. U.S. Food and Drug Administration. (2020). Inqovi (decitabine and cedazuridine) tablets: Prescribing information.
6. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).